F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance

Figure 1 High expression of F-box protein 22 in colon adenocarcinoma. A: F-box protein 22 (FBXO22) expression levels in various types of cancer were analyzed by the Tumor Immunity Evaluation Resource 2.0 database (red box: Tumor tissues; blue box: Normal tissues); B: FBXO22 expression levels in various types of cancer were analyzed by the GENT2 database (red box: Tumor tissues; blue box: Normal tissues); C: FBXO22 mRNA expression in tumoral (blue) and normal (yellow) tissues; D: Immunohistochemistry analysis of FBXO22 expression in a colorectal cancer patient tissue (n = 80). FBXO22 levels in cancer tissues and corresponding normal tissues. Representative images are shown (40 ×). ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs normal group; ^dP < 0.05 vs N group. ACC: Adrenocortical carcinoma; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical and endocervical cancers; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; DLBC: Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LAML: Acute myeloid leukemia; LGG: Lower grade glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenocarcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SARC: Sarcoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; TGCT: Testicular germ cell tumors; THCA: Thyroid carcinoma; THYM: Thymoma; UCEC: Uterine corpus endometrial carcinoma; UCS: Uterine carcinosarcoma; UVM: Uveal melanoma.